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Solid dosage forms such as tablets and capsules hold the highest share in the phar-
maceutical market despite the advancement in innovative dosage forms, such as lipo-
somes and transdermal delivery systems. Drugs dissolution from oral solid dosage forms
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The objective of the present investigation was to study
the influence of polyethylene glycol 4000 (PEG) and po-
lyvinylpyrrolidone K30 (PVP) on in vitro dissolution of
etoricoxib from solid dispersions. Preliminary studies
were carried out using a physical mixture of the drug and
carriers. Solid dispersions were prepared using the sol-
vent evaporation method.
A 32 factorial design was adopted in the solvent evapo-
ration method using the concentration of PEG and PVP
as independent variables. Full and reduced models were
evolved for dependant variables, such as the percentage
of drug release in 10 min (Q10), percentage of drug relea-
se in 30 min (Q30), percentage of drug release in 45 min
(Q45) and percent dissolution efficiency (DE). The reduced
models were validated using two check points. Q10 > 65%,
Q30 > 75%, Q45 > 85% and DE > 80% were used as con-
straints for the selection of an optimized batch. Contour
plots are presented for the selected dependant variables.
PEG was found to be more effective in increasing the drug
dissolution compared to PVP. Wettability study was car-
ried out for the pure drug and optimized batch. FT-IR
spectroscopy, microscopic study, differential scanning
calorimetry and X-ray diffraction study were carried out
in order to characterize the drug in solid dispersions.
Improved dissolution was attributed to decreased crys-
tallinity of the drug, improved wetting and solubilizing
effects of carriers such as PEG and PVP from the solid
dispersion of etoricoxib. In conclusion, dissolution of eto-
ricoxib can be modulated using appropriate levels of hy-
drophilic carriers.
Keywords: etoricoxib, solid dispersions, dissolution, poly-
ethylene glycol, polyvinylpyrrolidone, factorial design
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depends on the release of the drug from the dosage form and subsequent solubilization
of drug particles in physiological fluid. The dissolution characteristic of poorly water-
-soluble drugs has been and still remains a problem to the pharmaceutical industry be-
cause dissolution is the rate-limiting process in the absorption of these drugs from solid
dosage forms. Among the various approaches employed to improve the dissolution of
poorly soluble drugs, solid dispersion has been proven successful. Fast or immediate
drug dissolution from solid dispersions has been observed due to increased wettability,
improved dispersibility of drug particles, existence of the drug in amorphous form with
improved solubility and absence of aggregation of drug particles (1, 2). Literature shows
that the solvent evaporation method has been used for the preparation of solid disper-
sions for dissolution enhancement (3–7). Earlier studies show that solid dispersion sys-
tems increased the drug dissolution due to improved solubility, wettability and disper-
sibility using hydrophilic carriers (8–14).
The poor aqueous solubility and wettability of etoricoxib (CAS Registry No. 202409-
33-4, molecular formula C18H15ClN2O2S, molecular mass 358.84, Scheme 1), a non-steroidal
anti-inflammatory cyclo-oxygenase-II inhibitor drug, cause difficulties in the formulation of
oral dosage forms and lead to variable bioavailability.
To the best of our knowledge, no information is available on the improvement of
etoricoxib dissolution from solid dispersion systems using hydrophilic carriers. In order
to improve its solubility, dispersibility and wettability, hydrophilic carriers (polyethy-




Etoricoxib was obtained as a gift sample from Sun Pharmaceuticals Limited (India).
Polyvinyl pyrrolidone K30 and polyethylene glycol 4000 were purchased from Laser La-
boratories (India), potassium dihydrogen phosphate, sodium hydroxide and 2-propanol
from S. D. Fine-Chemicals Ltd. (India). Distilled water was used throughout the study.
286
B. N. Suhagia et al.: Preparation and characterization of etoricoxib-polyethylene glycol 4000 plus polyvinylpyrrolidone K30 solid











Physical mixing method. – A physical mixture was prepared by mixing etoricoxib (250
m) with PEG (1:5 ratio), PVP (1:5 ratio) or drug/PEG/PUP (1:2:2 ratio) in a glass mor-
tar by trituration for 10 min.
Solvent evaporation method. – Solid dispersions of etoricoxib and PEG/PVP were pre-
pared in drug to PEG/PVP ratios 1:1, 1:2, 1:3 and 1:5 (m/m) by the solvent evaporation
method. Etoricoxib was dissolved in 2-propanol to get a clear solution. PEG/PVP was
then dispersed as fine particles and the solvent was removed by evaporation on a water
bath at 60 °C. The dried mass was stored in dessicator until constant mass was obtained,
pulverized and passed through 250 m sieve.
Experimental design (15). – A 32 factorial design was adopted in the present study us-
ing PEG and PVP concentrations as independent variables at three levels: low, medium,
high. The batches of experimental design B1-B9 were prepared by the solvent evapora-
tion method and their composition is presented in Table I.
Dissolution study. – Dissolution of etoricoxib powder as such and from its physical
mixture or solid dispersions equivalent to 60 mg of etoricoxib was carried out with the
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Fig. 1. Dissolution profile of the preliminary and factorial design batches (mean ± SD, n = 3).
For abbreviations see Table I.
USP 23 Dissolution Test Apparatus (paddle) at 37  0.5 °C and 50 rpm using 900 mL
phosphate buffer (pH 7.4) as dissolution medium (n = 3) (16). Samples of dissolution
medium (5 mL) were withdrawn at predetermined time intervals and an equal amount
of fresh dissolution medium was added. Test samples were filtered through Whatman
filter paper No. 41 (Whatman Paper Limited, UK), suitably diluted and assayed for eto-
ricoxib at 284 nm using a blank solution as reference with a UV-Vis double-beam spec-
trophotometer (Model 160A, Shimadzu, Japan). The cumulative percentage of etoricoxib
dissolved was calculated using a regression equation generated from standard data.
Wettability study. – Drug powder, physical mixture or solid dispersion (3 g) was pla-
ced in a sintered glass funnel (55 mm i.d.). The funnel was plunged into a beaker con-
taining water so that the surface of the water in the beaker remained at the same level as
the powder in the funnel (17). Methylene blue powder (100 mg) was poured onto the
surface of the test sample. The time required for wetting the methylene blue powder
was measured. The average of three observations was calculated.
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D1 60 – – 149
D2 60 60 – 86
D3 60 120 – 77
D4 60 180 – 68
D5 60 300 – 61
D6a 60 300 – 82
P1 60 – 60 98
P2 60 – 120 89
P3 60 – 180 82
P4 60 – 300 70
P5b 60 – 300 92
B1 60 60 60 46
B2 60 60 120 41
B3 60 60 180 39
B4 60 120 60 40
B5 60 120 120 36
B6 60 120 180 37
B7 60 180 60 38
B8 60 180 120 37
B9 60 180 180 39
M1 60 180 120 37
M2 60 180 180 38
a Physical mixture of drug/PEG (1:5).
b Physical mixture of drug/PVP (1:5).
Infrared spectra. – Fourier transform infrared (FT-IR) spectra of etoricoxib, carriers,
physical mixtures and solid dispersions in carriers were obtained using potassium bro-
mide as the pellet making substance (Model 8400S, Shimadzu, Japan).
Microscopic analysis. – Photographs of the drug, carriers, physical mixtures and solid
dispersions were taken by placing a drop of their suspensions in cedar wood oil on a
glass slide with cover slip and viewing under the microscope fitted with a camera at the
required magnification.
X-ray diffraction study. – The X-ray diffraction study was carried out to characterize
the physical form of etoricoxib in solid dispersions of selected batches. Vacuum grease
was applied onto the glass slide to stick the sample. The sample was allowed to spread
on the slide to approximately 0.5 mm thickness. The slide was then placed vertically at
0° angle in an X-ray diffractometer (Model X’’Pert, Philips, The Netherlands) so that the
X-ray beam fell on it properly. The results were recorded over 0–100° (2) using a Cu-tar-
get X-ray tube and Xe-filled detector.
Differential scanning calorimetry study. – The powder sample was analyzed by differ-
ential scanning calorimetry (Model DT-60, Shimadzu) at a constant scanning speed of 10
°C min–1 from 0–300 °C. The 5–7 mg samples were accurately weighed into solid alumi-
num pans without seals.
RESULTS AND DISCUSSION
Only 60% of etoricoxib was released from the etoricoxib powder (batch D1) in 2 h.
Possible reasons for poor dissolution are its low aqueous solubility and poor wettability
(wetting time of etoricoxib 149 min) as compared to the etoricoxib – PEG (1:5) or eto-
ricoxib-PVP (1:5) physical mixture with wetting time of 82 and 92 min, respectively).
Eighty-two and seventy-seven percent of the drug were released from the physical mix-
tures (batch D6 and batch P5, respectively). Marginal improvement of the drug dissolu-
tion may be attributed to the hydrophilic nature of the polymers. The solvent evaporation
method was adopted for preparation of the solid dispersion because it is economical as
compared to the other methods. The etoricoxib-PEG dispersions have a higher percent-
age of drug released compared to etoricoxib-PVP dispersions. This may be due to the
more solubilizing and wetting effect of PEG compared to PVP. None of the formulated
batches (Fig. 1) showed  75% of drug release in 30 min. Hence, combinations of PEG
and PVP were used in the experimental design.
It was arbitrarily decided to obtain at least 75% drug release within 30 min from the
formulated dispersions. PEG or PVP were explored as hydrophilic carriers to improve
drug dissolution in the trials at different concentrations (Table I).
A 32 factorial design was adopted, using the amounts of PEG (X1) and PVP (X2) as
independent variables. The results of dependant variables, such as the percentage of drug
release in 10 min (Q10), percentage of drug release in 30 min (Q30), percentage of drug re-
lease in 45 min (Q45) and percentage dissolution efficiency (DE) are shown in Table II
and Fig. 1.
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Response surface curvature can be examined when the two variables are investigat-
ed at three levels. The design provides the following empirical second order equation
(full model):
Y = b0 + b1X1 + b2X2 + b11X12 + b22X22 + b12X1X2
where Y is the response, b0 is the intercept, b1 and b2 are coefficients of the main effects.
The coefficients with second order terms (b11 and b22) indicate the quadratic nature and
b12 is the regression coefficient for the interaction term. The estimated non-significant
coefficients should be omitted from the full model by adopting the significance test for
the regression coefficients. Microsoft EXCEL® may be used to identify non-significant
terms. A coefficient is significant if tcalculated > tcrit(v), where v denotes the degree of free-
dom of residual variances. The refined model (p < 0.05) for the Q10, Q30, Q45 and DE (%)
is shown in Table III.
It was arbitrarily decided to obtain Q10 > 65%, Q30 > 75%, Q45 > 85% and DE > 80%
from the formulated dispersions. A coefficient with a positive sign shows a synergistic
effect whereas a coefficient with a negative sign shows an antagonistic effect. The main
effects and the coefficient of the quadratic term b22 were found to be significant. Hence,
one cannot draw conclusions by considering the mathematical signs (positive or nega-
tive) of the main effects, such as b1 and b2. The refined model shows that the main ef-
fects, b1 and b2, and the quadratic term b11 are significant for Q10, Q30, Q45 and DE (%)
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Table II. Experimental runs and measured responsesa
Batch No. X1 X2 Q10 (%)b Q30 (%)c Q45 (%)d DE (%)e
B1 –1 –1 61.32 77.04 78.92 76.24
B2 –1 0 65.88 80.50 86.48 81.33
B3 –1 1 61.76 78.44 80.34 77.36
B4 0 –1 67.82 81.97 85.73 83.86
B5 0 0 67.61 85.61 89.15 86.00
B6 0 1 65.09 82.87 86.78 82.46
B7 1 –1 59.87 76.49 78.11 75.81
B8 1 0 57.71 79.46 81.63 78.34
B9 1 1 52.03 75.75 80.77 76.11
Factors and levels in the factorial design
Independent variables
Level
Low (–1) Medium (0) High (+1)
PEG 4000 (X1, mg) 60 120 180
PVP K30 (X2, mg) 60 120 180
a Detailed composition of batches B1-B9 is shown in Table I.
b Q10 – drug released in 10 min.
c Q30 – drug released in 30 min.
d Q45 – drug released in 45 min.
e DE (%) – percentage dissolution efficiency in 120 min.
while the interaction term b12 is significant only for Q30 and quadratic term b22 is signifi-
cant for Q30, Q45 and DE (%). PEG seems to be more effective compared to PVP in con-
trolling Q10, Q30, Q45 and DE (%), since coefficient b1 (3.2, 0.71, 0.87 and 0.74 for Q10, Q30,
Q45 and DE (%), respectively) is greater in magnitude compared to b2 (1.7, –0.26, 0.85
and –0.49 for Q10, Q30, Q45 and DE (%), respectively). The improved drug dissolution is
attributed to increased surface area or superior wetting of drug particles in the case of
Q30 and Q45. The decreased drug dissolution at high levels of variables (both PEG and
PVP 180 mg) in the case of Q30 and Q45 was attributed to the increased viscosity of disso-
lution medium due to the presence of hydrophilic carriers. Fig. 2 shows the contour plots
for Q10, Q30, Q45 and DE (%). The area that falls under the contour lines of Q10 > 65%,
Q30 > 75%, Q45 > 85% and DE > 80% shows different combinations of X1 and X2 that can
give acceptable drug dissolution.
Batches B2 and B4 to B6 met the selection criteria for Q10, Q30, Q45 and DE (%). Batch
B5 shows the highest dissolution efficiency among the selected batches (Table IV) and
hence it was considered to be an optimized batch in the present study.
The similarity factor (f2) (19) was calculated using B5 as a reference batch. Table V
shows that non-significant differences were observed between B5 and B2, B4, B6. The wetting
time for the pure drug and batch B5was found to be 149.5 and 36.0 min, respectively. It may
be assumed that improved drug dissolution was obtained due to increased wetting.
The FTIR spectra of pure etoricoxib showed characteristic peaks at 1599 cm–1 (C=N
stretching vibration), 1433 cm–1, 1300 cm–1, 1130 cm–1 and 1084 cm–1 (S=O stretching vi-
brations), and 839 cm–1, 781 cm–1 and 638 cm–1 (C-Cl stretching vibration), respectively.
The spectra of physical mixtures were equivalent to the spectra obtained by the addition
of polymers and the crystalline drug spectrum. This indicated that no interaction occurred
with simple physical mixing of the drug and hydrophilic polymers. The FTIR spectrum of
solid dispersion of etoricoxib with PEG and PVP showed a significant boarding O-H
stretching vibration peak characteristic of PEG (large band between 3483 cm–1 and 3119
cm–1) and a C-N stretching vibration peak characteristic of PVP (1238 cm–1) and S=O
stretching vibration characteristic of etoricoxib (1130 cm–1). This indicated that no interac-
tion occurred in dispersion of etoricoxib with PEG and PVP.
Photomicrographs of etoricoxib, PEG, PVP, their physical mixtures and solid disper-
sion are shown in Fig. 3. Analysis of photomicrographs revealed that the relatively
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Table III. Regression analysis of batches in the factorial design – summary
Response Model b0 b1 b2 b11 b22 b12 R2
Q10 Full 68.45 3.23 1.69 –7.08 –2.42 –2.07 0.9807
Refined 66.84 3.23 1.69 –7.08 – –2.07 0.9257
Q30 Full 85.55 0.71 –0.26 –5.53 –3.10 –0.53 0.9973
Refined 85.55 0.71 –0.26 –5.53 –3.10 – 0.9839
Q45 Full 89.88 0.87 0.85 –6.18 –3.98 –0.31 0.9308
Refined 89.88 0.87 0.85 –6.18 –3.98 –0.31 0.9308
DE (%) Full 86.25 0.74 –0.49 –6.54 –3.27 –0.21 0.9831
Refined 86.25 0.74 –0.49 –6.54 –3.27 – 0.9815
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Table IV. Dissolution efficiency





a Defined as the area under the dissolution curve up to a certain time,
expressed as percentage of the area of the rectangle described by 100%
dissolution during the same time (18).
Fig. 2. Contour plots for: a) Q10, b) Q30, c) Q45 and d) DE (%). Note: Transformed value –1, 1 for
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Fig. 3. Photomicrographs of: a) pure etoricoxib, b) PEG, c) PVP, d) batch B5.
a) b)
c) d)
larger polyhedral crystalline forms of PEG and PVP and the elongated/oval crystals of
etoricoxib, clearly visible in their physical mixtures, were transformed to less crystalline
structures in their solid dispersions. These observations provided the evidence of solid
dispersion formation (20).
The X-ray diffraction pattern (XRD) of the pure drug and batch B5 are shown in Fig.
4. Characteristic peaks appeared in the XRD pattern of the drug at a diffraction angle of
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Fig. 4. X-ray diffraction of: a) batch D1, b) batch B5.
a)
b)
9.6, 11.7, 15.4, 16.4, 18.1, 19.4, 22.7, 24.1, 29.3, 31.2, 39.2, 43.3 and 45.1° suggesting that the
drug is present as a crystalline material. Solid dispersion showed all the peaks shown by
the drug (15.2, 19.2, 21.7, 23.4, 27.0, 36.2, 39.8 and 43.3); however, the intensity of the
peaks found was slightly reduced when compared to that of the drug. It was also ob-
served that some peaks shown by pure etoricoxib are absent and the intensity of peaks
found was markedly reduced in the XRD patterns of solid dispersion. The result indi-
cates that the drug in solid dispersion is amorphous as compared to the pure drug.
Hence, increased dissolution of the drug was observed (21).
DSC curves of the pure drug (batch D1) and its solid dispersion (batch B5) are
shown in Fig. 5. DSC curve of batch D1 showed one sharp endothermic peak at 140.68
°C corresponding to etoricoxib. The DSC curve of batch B5 showed two endothermic
peaks, a sharp peak at 57.31 °C corresponding to PEG and a broad peak at 125.88 °C cor-
responding to etoricoxib in solid dispersion. Peak temperature in solid dispersions
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Fig. 5. DSC scans of: a) batch D1, b) batch B5.
a)
b)
shifted slightly to lower temperature with respect to the drug alone and there was a de-
crease in H value of batch B5 (–273.19 J g–1) compared to the pure drug (–88.52 J g–1).
These phenomena could be attributed to the amorphous form of the drug in solid dis-
persions (22).
The mixture of PEG and PVP in dispersion systems rendered the drug more hydro-
philic and more wettable in the dissolution medium. This is the prime reason for rapid
and complete drug dissolution from solid dispersion systems. Decreased crystallinity and
increased wetting of the particles may be considered as major contributors to the enhan-
ced etoricoxib dissolution from a solid dispersion system containing PEG and PVP.
To validate the evolved mathematical models (reduced models for Q10, Q30, Q45
and DE (%), two check points were selected. Two batches (M1 and M2, Table I) were pre-
pared and evaluated. The observed and predicted values are shown in Table VI. Good
agreement was found between the observed and predicted values. Thus, it may be con-
cluded that the evolved models may be used for theoretical prediction of responses
within the factor space.
CONCLUSIONS
Solid dispersions prepared from hydrophilic polymers using the solvent evapora-
tion method were effective in improving drug dissolution. The dispersion containing
PEG and PVP (batch B5) shows acceptable dissolution compared to the PEG or PVP dis-
persion or pure drug. The study revealed that optimum levels of hydrophilic carriers en-
sure a prompt and complete dissolution of etoricoxib from solid dispersions that are
used in oral pharmaceutical formulations.
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Table VI. Observed and predicted results of check points
Response
Batch M1 (X1 = 0.5, X2 = 0.5) Batch M2 (X1 = 0.75, X2 = 0.5)
Observed Predicted Observed Predicted
Q10 (%) 64.3 63.1 60.9 59.8
Q30 (%) 83.6 83.0 81.5 81.1
Q45 (%) 89.0 87.4 85.7 85.3
DE (%) 84.9 83.5 82.7 83.5
For abbreviations see Table II.
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S A @ E T A K
Priprava i karakterizacija ~vrstih disperzija etorikoksiba s polietilenglikolom
4000 i polivinilpirolidonom K30
BHANUBHAI N. SUHAGIA, HARESH M. PATEL, SHAILESH A. SHAH, ISHWARSINH RATHOD i VIJAY K. PARMAR
U radu je prou~avan utjecaj polietilenglikola 4000 (PEG) i polivinilpirolidona K30
(PVP) na in vitro osloba|anje etorikoksiba iz ~vrstih disperzija. Preliminarni pokusi pro-
vedeni su sa smjesom ljekovite tvari i polimernih nosa~a. ^vrste disperzije pripravljene
su metodom uparavanja otapala. Za ovu metodu razvijen je 32 faktorijalni dizajn koris-
te}i koncentraciju PEG i PVP kao nezavisne varijable. Za zavisne varijable razvijeni su
potpuni i reducirani modeli, kao {to su postotak oslobo|ene ljekovite tvari u 10 (Q10), 30
(Q30) ili 45 minuta (Q45) i postotak u~inkovitosti osloba|anja (DE). Reducirani modeli su
validirani pomo}u dviju kontrolnih to~aka. Q10 > 65%, Q30 > 80%, Q45 > 85% i DE > 80%
su uporabljeni kao ograni~enja za izbor optimirane serije. Prikazane su konturne linije
za pojedine zavisne varijable.
Osloba|anje lijeka bilo je u~inkovitije iz pripravaka s PEG-om. Vla`enje je prou~a-
vano za ~istu ljekovitu supstanciju i optimiranu seriju. Za karakterizaciju ljekovite tvari
u ~vrstim disperzijama kori{tene su FT-IR spektroskopija, mikroskopske studije, diferen-
cijalna pretra`na kalorimetrija i difrakcija rentgenskim zrakama. Pove}ano osloba|anje
posljedica je smanjene kristalini~nosti ljekovite tvari, poja~anog vla`enja i solubilizacij-
skog u~inka polimernih nosa~a u disperzijama. Zaklju~eno je da se osloba|anje etori-
koksiba mo`e modulirati promjenom koli~ine hidrofilnih nosa~a.
Klju~ne rije~i: etorikoksib, ~vrsta disperzija, osloba|anje, polietilenglikol, polivinilpirolidon, fakto-
rijalni dizajn
Department of Quality Assurance, L. M. College of Pharmacy, Navrangpura, Ahmedabad-380 009, India
298
B. N. Suhagia et al.: Preparation and characterization of etoricoxib-polyethylene glycol 4000 plus polyvinylpyrrolidone K30 solid
dispersions, Acta Pharm. 56 (2006) 285–298.
